The shareholder-rights firm said it is examining whether HCA Healthcare misled investors before preliminary Q2 2026 results, a full-year guidance cut tied to an unfavorable payer mix, and a nearly 7% share decline.
The Schall Law Firm said it is investigating HCA Healthcare, Inc. for potential securities-law violations tied to the company’s disclosures to investors. The inquiry focuses on whether HCA made false or misleading statements, or omitted material information, before reporting preliminary Q2 2026 financial results on July 14, 2026. HCA also sharply lowered its full-year 2026 guidance, attributing the change to an unfavorable payer mix, and its shares fell by almost 7% the same day. The law firm said it is seeking to hear from shareholders who suffered losses, indicating an early-stage shareholder investigation.